Member Info for Nolupus

Everything is possible , even a TR-1 from Avion :-)

Would be a good time for them to be averaging down ??

Let’s see what happens next

It’s a long and twisty road …

But who knows where we will be this time next year ?

Patience is the key

Draye,

Asking about financing is normal as only two things are important in biotechs , imo
1) science
2) finance

Good to see that Tim and Art are moving forward as quickly as possible …

Would have liked to see news on the financing though ..

Not long to wait , should be interesting :-)

If one is relying on twitter to make investment decisions … lol , well I think my crystal ball is more reliable :-)

Leas,

That all depends on Avion as you are suggesting…

The road is long but we are moving in the right direction and gaining pace so patience is necessary, imo

I would like to see a Big pharma partnership at this stage but not a buy out as this would not be in shareholders best interests, imo

Waiting patiently on partnership news …:

Manifesto,

A chip and a chair , comes to mind :-)

So near and yet so far ….

Hoping for the best but prepared for the worst :-)

Never thought I would see SNG at this level ..

Opportunity or a dead duck ?

Let’s see

Leas,

I cannot agree with you on that front as IMM did’nt sell any drugs but they did sell a license to Cephalon as they did to Avion …

I cannot see personally how IMM will make money out of being an agent for Avion ( especially as the initial project is on ´ a named patient ‘ basis …
Avion’s products as far as I know have no European authorizations, so lots of work to be done before any real revenue can be expected , imo

Long road to go before the dollar but it’s good to see some upward movement…

Let’s see what happens next

Draye,

I think the 6 million MC shows that the market is sir far not convinced of the near time value of IMM . There is as you say Potential, imo , but the potential needs financing and we need to know where the funds are coming from , IMO
I personally think that CIDP has the most potential and am awaiting news on that front , but everyone to their own opinions as per usual

Michael2021,

Keep the faith like Frits ( average 35p) but still ´ strong buy ‘

Easyp ,

It seems to have a biological effect but we need to transform that biological effect into a curative effect ..

Still work needs done but it is encouraging !

It’s a pity to have a blinkered outlook ( or should I say , a ST trade ) to say such complete nonsense…

´ IMO, we could get approval if it works as well as expected with the new guidance, by the end of 2023 ? ‘

One can take a horse to water but one cannot force them to drink , comes to mind … one cannot ignore the complexities of clinical trials and their timescales whilst being an investor in biotechs , imo

But anyway , I am ****hing against the wind as per usual , as investor timescales are not the same as clinical timescales…

Maidit308,

You say
‘ the way it sound to me is that P2 / P3 will run alongside each other at the same time‘

It’s completely in contradiction to what the RNS states …

They do the first part of the study ( P2 dosing ) then after choosing the ´ new dosing level ‘ they go straight into the P3 part of the trial if the interim results are satisfactory

One after the other is not running alongside !

Draye,

Tim confirms what I am saying in that video …Listen carefully !